Cancer Therapy

Analysis of Genasense trial confirms major efficacy variables in patients with melanoma

Published in Cancer Weekly, February 28th, 2006

Genta Incorporated (GNTA) announced the presentation of analyses that confirmed the major efficacy variables from the company's randomized phase III trial of Genasense (oblimersen) plus chemotherapy in patients with advanced metastatic melanoma.

The data were presented in Paris, France at the 17th International Congress on Anticancer Treatment by Alexander Eggermont from the Daniel den Hoed Cancer Center, Erasmus University, Rotterdam, The Netherlands. Eggermont is the current president of the European Organization on Research and Treatment of Cancer (EORTC).

Recent studies conducted by the EORTC and other groups have shown that elevation of serum...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-02-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry